MRZM (Marizyme) Total Operating Expense: $12.49 Mil (TTM As of Sep. 2024)


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme Total Operating Expense?

Marizyme MRZM -99.67% 12 Total Operating Expense is $12.49 Mil as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

Marizyme's Total Operating Expense for the three months ended in Sep. 2024 was $1.36 Mil. Marizyme's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 was $12.49 Mil.

Marizyme Total Operating Expense Related Terms

Marizyme Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Marizyme's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme Total Operating Expense Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 5.94 8.95 13.15 20.30

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.99 8.15 1.40 1.59 1.36
MRZM
12GF Score
Marizyme Inc MRZM
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $12.49 Mil mean?
Marizyme (MRZM) has a Total Operating Expense of $12.49 Mil as of Sep. 2024. Total operating expense is the primary recurring expense associated with central operations. View historical data on Marizyme and its competitors.
Is Marizyme's Total Operating Expense too high?
Marizyme's current Total Operating Expense is $12.49 Mil. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's Total Operating Expense compare to CNBX and XSNX?
Marizyme's Total Operating Expense of $12.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Marizyme and its competitors. Marizyme's current Total Operating Expense is $12.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current Total Operating Expense of $12.49 Mil. The current Total Operating Expense is $12.49 Mil. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Marizyme (MRZM), the current Total Operating Expense is $12.49 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price